Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2010 - 2024)
Tonix Pharmaceuticals Holding (TNXP) posted Non-Current Debt of $8.6 million for Q4 2024, up 67.25% on a QoQ basis from $5.2 million in Q3 2024, and down 21.36% year-over-year from $11.0 million in Q1 2024.
Powered by 
Analysis
Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2010 - 2024) Analysis & Trends
Tonix Pharmaceuticals Holding has reported Non-Current Debt for 4 years, with the latest figure at $8.6 million in Q4 2024.
- On a quarterly basis, Non-Current Debt fell 21.36% year-over-year to $8.6 million in Q4 2024; TTM through Dec 2024 was $8.6 million, a 21.36% decrease from a year earlier, with the FY2024 full-year figure at $8.6 million, down 21.36% from the prior year.
- Non-Current Debt was $8.6 million for Q4 2024 at Tonix Pharmaceuticals Holding, up from $5.2 million in the prior quarter.
- The five-year high for Non-Current Debt was $11.0 million in Q4 2023, with the low at $5.2 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 60.50 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 17.02 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 882.16 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | Tonix Pharmaceuticals Holding | 220.65 Mn | 220.65 Mn | 12.84 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 8.65 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.67 Mn |
| Mar 31, 2024 | 6.16 Mn |
| Dec 31, 2023 | 11.00 Mn |
| Jun 30, 2011 | 10,000.00 |
| Dec 31, 2010 | 10,000.00 |